Glaukos (GKOS) Cash from Investing Activities Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -41.67% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -472.46% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -16.93% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -111.03% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -40.94% |
| 10 | Glaukos | 6.00 Bn | 5.90 Bn | 117.23 Mn | 40.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.26% |
| Dec 31, 2025 | -43.49% |
| Sep 30, 2025 | -29.34% |
| Jun 30, 2025 | -60.80% |
| Mar 31, 2025 | -84.35% |
| Dec 31, 2024 | 49.31% |
| Sep 30, 2024 | 46.94% |
| Jun 30, 2024 | 167.50% |
| Mar 31, 2024 | -11.38% |
| Dec 31, 2023 | -55.16% |
| Sep 30, 2023 | 27.69% |
| Jun 30, 2023 | 48.21% |
| Mar 31, 2023 | -188.55% |
| Dec 31, 2022 | -30.59% |
| Sep 30, 2022 | 99.89% |
| Jun 30, 2022 | 162.45% |
| Mar 31, 2022 | -50.99% |
| Dec 31, 2021 | 20.64% |
| Sep 30, 2021 | -63.79% |
| Jun 30, 2021 | -40.97% |
| Mar 31, 2021 | -59.36% |
| Dec 31, 2020 | 23.38% |
| Sep 30, 2020 | -401.09% |
| Jun 30, 2020 | -161.56% |
| Mar 31, 2020 | 31.98% |
| Dec 31, 2019 | 168.83% |
| Sep 30, 2019 | 26.28% |
| Jun 30, 2019 | 49.32% |
| Mar 31, 2019 | 41.34% |
| Dec 31, 2018 | 36.74% |
| Sep 30, 2018 | -218.85% |
| Jun 30, 2018 | 328.92% |
| Mar 31, 2018 | -190.19% |
| Dec 31, 2017 | -197.86% |
| Sep 30, 2017 | -368.86% |